TOFACITINIB CITRATE

Search structure
Trade Names:
Synonyms:
Status: Approved (2012)
Entry Type: Small molecule
Molecule Category: Salt
UNII: O1FF4DIV0D
Parent Compound: TOFACITINIB

Structure
InChI Key SYIKUFDOYJFGBQ-YLAFAASESA-N
Smile C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
InChI
InChI=1S/C16H20N6O.C6H8O7/c1-11-5-8-22(14(23)3-6-17)9-13(11)21(2)16-12-4-7-18-15(12)19-10-20-16;7-3(8)1-6(13,5(11)12)2-4(9)10/h4,7,10-11,13H,3,5,8-9H2,1-2H3,(H,18,19,20);13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)/t11-,13+;/m1./s1

Physicochemical Descriptors

Property Name Value
Molecular Formula C22H28N6O8
Molecular Weight 504.5
AlogP 1.54
Hydrogen Bond Acceptor 5.0
Hydrogen Bond Donor 1.0
Number of Rotational Bond 3.0
Polar Surface Area 88.91
Molecular species NEUTRAL
Aromatic Rings 2.0
Heavy Atoms 23.0

Pharmacology

Action Mechanism of Action Reference
INHIBITOR Janus Kinase (JAK) inhibitor Expert

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Arthritis, Rheumatoid 4 D001172 ClinicalTrials
Lupus Erythematosus, Systemic 0 D008180 ClinicalTrials
Lupus Erythematosus, Discoid 0 D008179 ClinicalTrials

Related Entries

Parent

Adverse Reactions

SOC By Demographic Distribution
System Organ Classification (SOC)
Relative Frequency (%)
General disorders and administration site conditions
16.5
Musculoskeletal and connective tissue disorders
11.67
Infections and infestations
9.85
Respiratory, thoracic and mediastinal disorders
9.8
Gastrointestinal disorders
8.62
Nervous system disorders
7.7
Injury, poisoning and procedural complications
6.4
Skin and subcutaneous tissue disorders
5.33
Investigations
3.84
Vascular disorders
3.29
Cardiac disorders
3.23
Psychiatric disorders
2.62
Immune system disorders
2.2
Renal and urinary disorders
2.15

Cross References

Resources Reference
ChEBI 71197
ChEMBL CHEMBL2103743
EPA CompTox DTXSID80202404
FDA SRS O1FF4DIV0D
Guide to Pharmacology 5677
KEGG D09970
PDB MI1
PubChem 10174505
SureChEMBL SCHEMBL1374185
ZINC ZINC03818808
CONTENTS